Edition:
United Kingdom

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

26.73USD
16 Feb 2018
Change (% chg)

$-0.36 (-1.33%)
Prev Close
$27.09
Open
$27.19
Day's High
$27.38
Day's Low
$25.62
Volume
60,075
Avg. Vol
63,816
52-wk High
$40.56
52-wk Low
$19.85

Chart for

About

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical... (more)

Overall

Beta: --
Market Cap(Mil.): $832.70
Shares Outstanding(Mil.): 26.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Reata Announces Improvements In Kidney Function With Bardoxolone Methyl Maintained For Two Years In Pah Patients From Lariat Trial

* REATA ANNOUNCES IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE METHYL MAINTAINED FOR TWO YEARS IN PAH PATIENTS FROM LARIAT TRIAL Source text for Eikon: Further company coverage:

12 Feb 2018

BRIEF-Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko

* REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK)

07 Dec 2017

BRIEF-Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock‍​

* Files for offering of up to $50.0 million of shares of Class A common stock‍​ - SEC filing Source text : (http://bit.ly/2AG2XNP) Further company coverage:

13 Nov 2017

BRIEF-Reata Pharmaceuticals Q3 loss per share $0.50

* Reata Pharmaceuticals Inc announces third quarter 2017 financial and operating results

13 Nov 2017

BRIEF-Reata Pharmaceuticals enters first amendment to loan and security agreement​

* Reata Pharmaceuticals says ‍on November 3, co entered into a first amendment to loan and security agreement​ - SEC filing

07 Nov 2017

BRIEF-Reata provides update on Bardoxolone Methyl from American Society of Nephrology Kidney Week Meeting

* Reata provides update on bardoxolone methyl from the american society of nephrology kidney week meeting

06 Nov 2017

BRIEF-Reata Pharmaceuticals says top-line data to be available in 2019 for omaveloxolone​

* Reata Pharmaceuticals Inc - ‍announces first patient enrolled in Part 2 of Moxie study of omaveloxolone for treatment of Friedreich's Ataxia​

23 Oct 2017

BRIEF-Reata Pharma receives orphan drug designation for Omaveloxolone

* Reata Pharmaceuticals Inc receives orphan drug designation for Omaveloxolone for the treatment of malignant melanoma

13 Sep 2017

Earnings vs. Estimates